Pharmacotherapy of chronic heart failure: Current status and future aspects

European Heart Journal, Supplement

Volumn 4, Issue I, 2002, Pages

  Fuchs, M ^a   Drexler, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Calcium; Chronic heart failure; Cytokines; Neuroendocrine system; NO; Regeneration; Therapy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCINEURIN; CALCIUM; CARVEDILOL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; KB R 7785; NITRIC OXIDE; PHOSPHOLAMBAN; PROTEIN INHIBITOR; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VALSARTAN;

APOPTOSIS; CALCIUM HOMEOSTASIS; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; EXERCISE; HEART FAILURE; HEART HYPERTROPHY; HUMAN; MYOBLAST; NEUROENDOCRINE SYSTEM; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

EID: 0036900047     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90116-1     Document Type: Conference Paper

References (37)

1. Pitt B, Zannad F, Remme WJ, Cody R, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
2. Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonism in heart failure. J Cardiovasc Pharmacol 2000; 35(suppl 2): S69-73.
3. Kalra P, Moon J, Coats A. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195.
4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvediolo on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
5. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
6. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
7. Drexler H, Coats AJ. Explaining fatigue in congestive heart failure. Annu Rev Med 1996; 47: 241-56.
8. Jin H, Yang R, Awad TA, et al. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation 2001; 103: 736-42.
9. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 391-8.
10. Wollert KC, Drexler H The role of interleukin-6 in the failing heart. Heart Fail Rev 2001; 6: 95-103.
11. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-9.
12. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995; 92: 4862-6.
13. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999; 99: 546-51.
14. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: Possible implication in left ventricular remodeling. Circulation. 1998; 98: 149-56.
15. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995; 91: 1520-4.
16. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 1998; 275: H250-8.
17. Negoro S, Kunisada K, Tone E, et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000; 47: 797-805.
18. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97: 189-98.
19. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Decreased activation of the JAK2-STAT3 signaling pathwa in patients with end-stage dilated cardiomyopathy. Eur Heart J 2002; 4: 501.
20. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-65.
21. 11 in cardiomyocytes. Nat Med 2001; 7: 1236-40.
22. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM 12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 35-40.
23. Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin 11 type 1A receptor knockout mice. Circulation 1998; 97: 1952-9.
24. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99: 11363-8.
25. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104: 1286-91.
26. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376-81.
27. Melov S, Ravenscroft J, Malik S, et al. Extension of life-span with superoxide dismutase/catalase mimetics. Science 2000; 289: 1567-9.
28. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-37.
29. Hasenfuss G, Reinecke H, Studer R, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 1996; 91(suppl 2): 17-22.
30. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793-8.
31. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308-11.
32. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med 2000; 32: 572-8.
33. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999;99:313-22.
34. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279-80.
35. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
36. Strauer BE, Brehm M, Zeus T, et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch Med Wochenschr 2001; 126: 932-8.
37. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344-9.